Accessibility Menu
IceCure Medical logo

IceCure Medical(NASDAQ) ICCM

Current Price$3.26
Market Cap$9.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+11%
5 Year-99%
1 Year-89%
1 Month-38%
IceCure Medical last closing stock price
MetricPriceDate
Last closeUSD 3.362026-07-21
IceCure Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.67%USD 3.602026-07-14
1 month-37.78%USD 5.402026-06-18
3 month-68.66%USD 10.722026-04-22
Year to date-81.64%USD 18.302025-12-31
1 year-88.97%USD 30.452025-07-21
3 year-90.67%USD 36.002023-07-21
5 year-98.91%USD 307.202021-07-22
Since inception+11.48%USD 3.012013-11-07

IceCure Medical Financials at a Glance

Market Cap

$9.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.57M

Net Income (TTM)

-$15.74M

EPS (TTM)

-$6.95

P/E Ratio

-0.48

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$3.26

Volume

50

Open

$3.31

Previous Close

$3.36

Daily Range

$3.26 - $3.31

52-Week Range

$2.12 - $42.00

Estimated Earnings Date

Aug 12, 2026

ICCM News

featured-earnings-leadership-highlights.png

IceCure Medical Advances FDA Review

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About IceCure Medical

IceCure Medical Ltd is a medical device company based in Caesarea, Israel, focused on developing innovative cryoablation solutions for treating tumors. Founded in 2006, the company aims to enhance patient outcomes through its advanced ProSense system, specifically designed for breast tumors.

Products and Services
  • ProSense system for cryoablation therapy
  • Innovative solutions for tumor treatment
  • Research and development in medical devices
Growth Outlook
  • Recent quarterly revenue increased to $911,000
  • Strong market potential in the medical device sector
  • Focus on expanding product offerings and market reach
Financial Highlights
  • Trailing twelve months revenue of $3.5 million
  • Cash and cash equivalents of $8.1 million as of March 2026
  • Current ratio of 2.52 indicates strong liquidity position
IceCure Medical Ltd operates in the medical devices industry, specializing in cryoablation technology. The ProSense system represents a significant advancement in tumor treatment, offering a non-invasive alternative to traditional methods. The company has shown promising growth, with a recent quarterly revenue of $911,000, reflecting an upward trend in demand for its innovative solutions. The financial position of IceCure Medical is bolstered by a solid cash reserve of $8.1 million, providing a buffer for ongoing research and development efforts. The current ratio of 2.52 suggests that the company is well-positioned to meet its short-term obligations, indicating a healthy liquidity status. With a focus on expanding its product offerings and market presence, IceCure Medical is poised for growth in the evolving healthcare landscape. The company's commitment to innovation and patient care positions it as a noteworthy player in the medical device sector.
AI Generated • Jun 23, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

69

CEO

Eyal Shamir, MBA

Website

www.icecure-medical.com

Headquarters

Caesarea, HA 3079504, IL

ICCM Financials

Key Financial Metrics (TTM)

Gross Margin

36.55%

Operating Margin

-835.01%

Net Income Margin

-441.60%

Return on Equity

-211.73%

Return on Capital

-162.86%

Return on Assets

-118.34%

Earnings Yield

-2.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.81M

Volume

50

Avg. Volume

3.32M

Financials (TTM)

Gross Profit

$1.30M

Operating Income

-$29.77M

EBITDA

-$15.41M

Operating Cash Flow

-$15.25M

Capital Expenditure

-$81.77K

Free Cash Flow

-$15.34M

Cash & ST Invst.

$8.12M

Total Debt

$139.00K

IceCure Medical Performance Analysis

IceCure Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,085,000-25.4%
20232023-12-31USD 3,229,0004.7%
20242024-12-31USD 3,291,0001.9%
20252025-12-31USD 3,379,0002.7%
IceCure Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-27.6%
Q32025-09-3061.9%
Q42025-12-3150.5%
Q12026-03-31-28.8%
IceCure Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.5032.3%
20232023-12-31USD -9.45-30.0%
20242024-12-31USD -8.86-6.2%
20252025-12-31USD -7.10-19.8%
IceCure Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-307.9%
Q32025-09-30-5.4%
Q42025-12-313.5%
Q12026-03-310.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$911.00K

+25.7%

Gross Profit

$295.00K

+35.3%

Gross Margin

32.38%

N/A

Market Cap

$9.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$136.67K

N/A

Employees

69

N/A

Net Income

-$4.27M

-19.1%

EBITDA

-$4.18M

-17.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.12M

+34.4%

Total Debt

$139.00K

-63.4%

Accounts Receivable

$274.00K

-79.9%

Inventory

$2.65M

+30.0%

Long Term Debt

$5.00K

-95.4%

Short Term Debt

$134.00K

-50.7%

Return on Assets

-1.18%

N/A

Return on Invested Capital

-3.50%

N/A

Free Cash Flow

-$4.32M

-6.8%

Operating Cash Flow

-$4.27M

-5.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDCXMedicus Pharma Ltd. Common Stock
$0.37-3.92%
CTSOCytosorbents Corporation
$0.40+1.63%
TELATELA Bio, Inc.
$0.74+2.15%
TELOTelomir Pharmaceuticals, Inc. Common Stock
$1.11+2.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.08+0.05%
SMCISuper Micro Computer
$31.05+0.22%
RIGTransocean
$5.30+0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.66+0.01%

Questions About ICCM

What is the current price of IceCure Medical?

IceCure Medical is trading at $3.26 per share.

What is the 52-week range for IceCure Medical?

Over the past 52 weeks, IceCure Medical has traded between $2.12 and $42.00.

How much debt does IceCure Medical have?

As of the most recent reporting period, IceCure Medical reported total debt of $139.00K.

How much cash does IceCure Medical have on hand?

IceCure Medical reported $8.12M in cash and cash equivalents in its most recent financial results.

What is IceCure Medical’s dividend yield?

IceCure Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services